The Effect of Silymarin on Liver Enzymes in Patients Taking Isotretinoin: A Randomized Clinical Trial Publisher Pubmed



Mirnezami M¹ ; Jafarimanesh H² ; Rezagholizamenjany M³ ; Alimoradian A⁴ ; Ranjbaran M^{5, 6} Show Affiliations
Source: Dermatologic Therapy Published:2020

Abstract

The aim of the present study was to investigate the effect of silymarin (Livergol) on liver enzymes in patients taking isotretinoin (Roaccutane). In this double-blind clinical trial, 74 patients with acne and taking isotretinoin were randomly assigned into intervention (N = 37) and control (N = 37) groups. The intervention group received a 140 mg Livergol capsule per day for 30 days. The control group received a starch-containing capsule as a placebo once a day for 30 days. Liver enzyme levels were measured before and after the intervention. The data were analyzed using chi-square test, Independent t test, paired sample t test and analysis of covariance (ANCOVA). The results showed no statistically significant difference between the intervention and control groups at the beginning of study in levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) (p >.05). At the end of the study, a statistically significant difference was observed between the two groups in levels of AST and ALT (p <.05). Livergol prevented liver enzymes from increasing, so it can be used as an effective, low-cost, and low-complication treatment for the problem of increased levels of liver enzymes following the use of isotretinoin. © 2020 Wiley Periodicals, Inc.